4-Hydroxytamoxifen (Afimoxifene)

Overview

4-Hydroxytamoxifen (afimoxifene) is a non-peptide selective estrogen receptor modulator (SERM) and triphenylethylene derivative that serves as a major, highly potent active metabolite of tamoxifen. It is not an approved drug in the US or elsewhere; human data are limited to investigational Phase II trials of a topical gel formulation for cyclical mastalgia and breast density reduction. Tamoxifen and other SERMs are prohibited at all times under WADA category S4.2 (anti-estrogenic substances); as tamoxifen's active metabolite and an anti-estrogenic SERM, 4-hydroxytamoxifen would very likely be captured by similar-structure-or-effect language, though explicit naming was not confirmed.

Mechanism of Action

Afimoxifene is a competitive antagonist/partial agonist at estrogen receptors alpha and beta, exhibiting tissue-selective activity characteristic of SERMs. Receptor-binding studies on estrogen receptors isolated from human breast carcinoma found 4-hydroxytamoxifen binds ER with affinity equal to estradiol and 25–50× higher than tamoxifen itself, which is why it is considered tamoxifen's principal active metabolite despite low circulating abundance (2–18% of parent drug). Unlike tamoxifen and endoxifen, whose formation depends on hepatic CYP2D6/CYP3A4 activity, 4-hydroxytamoxifen is already the pharmacologically active hydroxylated species, which is the rationale for delivering it directly (e.g., as a topical gel) to bypass variable CYP2D6-dependent bioactivation of oral tamoxifen.

Research Summary

No human data exist for oral administration; all human evidence comes from investigational topical gel trials. A randomized, double-blind Phase II trial in premenopausal women with cyclical mastalgia (2 mg vs 4 mg vs placebo gel over 4 menstrual cycles) found the 4 mg dose significantly improved pain scores versus placebo with no serious drug-related adverse events and no observed changes in menstrual pattern or plasma hormone levels. Additional Phase II trials have evaluated topical 4-hydroxytamoxifen gel for reducing mammographic breast density and as a presurgical/DCIS intervention, though current trial status is unconfirmed. In MCF-7 human breast cancer cells in vitro, 4-hydroxytamoxifen competitively inhibits estrogen receptor signaling, inducing growth arrest and apoptosis. In ovariectomized Sprague-Dawley rats, 4-hydroxytamoxifen produced uterotrophic changes (increased luminal epithelial cell height) but far less uterine weight gain than estradiol, consistent with partial-agonist rather than full-agonist activity. In mouse uterus, 4-hydroxytamoxifen exposure is uterotrophic (estrogen-agonist-like), contrasting with more antagonist-dominant behavior in rat uterus.

Reported Side Effects

• Well tolerated at 2–4 mg/day topical gel in short-duration trial (4 cycles)
• No long-term human safety or systemic-exposure safety data available
• Theoretical SERM class risks (endometrial/uterotrophic effects seen preclinically)
• Uterotrophic partial-agonist activity observed in rodent studies
• Likely prohibited under WADA S4.2 anti-estrogenic substances

Compare 4-Hydroxytamoxifen (Afimoxifene) with Others

Research References

• PubChem Compound Summary for CID 449459, (Z)-4-Hydroxytamoxifen.
• ChEBI:44616 — afimoxifene.
• Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma. 1981. PMID 7317574.
• A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. 2007. PMID 17351746.

Frequently asked questions

Has 4-Hydroxytamoxifen (Afimoxifene) been independently lab-tested?

Disclosed Labs has collected 1 Certificate of Analysis (COA) for 4-Hydroxytamoxifen (Afimoxifene) from 1 independent testing lab. 1 vendor has submitted material for testing. Products average 98.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/4-hydroxytamoxifen/testing.

How does 4-Hydroxytamoxifen (Afimoxifene) work?

Afimoxifene is a competitive antagonist/partial agonist at estrogen receptors alpha and beta, exhibiting tissue-selective activity characteristic of SERMs. Receptor-binding studies on estrogen receptors isolated from human breast carcinoma found 4-hydroxytamoxifen binds ER with affinity equal to estradiol and 25–50× higher than tamoxifen itself, which is why it is considered tamoxifen's principal active metabolite despite low circulating abundance (2–18% of parent drug). Unlike tamoxifen and endoxifen, whose formation depends on hepatic CYP2D6/CYP3A4 activity, 4-hydroxytamoxifen is already the pharmacologically active hydroxylated species, which is the rationale for delivering it directly (e.g., as a topical gel) to bypass variable CYP2D6-dependent bioactivation of oral tamoxifen.

What does the research say about 4-Hydroxytamoxifen (Afimoxifene)?

No human data exist for oral administration; all human evidence comes from investigational topical gel trials. A randomized, double-blind Phase II trial in premenopausal women with cyclical mastalgia (2 mg vs 4 mg vs placebo gel over 4 menstrual cycles) found the 4 mg dose significantly improved pain scores versus placebo with no serious drug-related adverse events and no observed changes in menstrual pattern or plasma hormone levels. Additional Phase II trials have evaluated topical 4-hydroxytamoxifen gel for reducing mammographic breast density and as a presurgical/DCIS intervention, though current trial status is unconfirmed. In MCF-7 human breast cancer cells in vitro, 4-hydroxytamoxifen competitively inhibits estrogen receptor signaling, inducing growth arrest and apoptosis. In ovariectomized Sprague-Dawley rats, 4-hydroxytamoxifen produced uterotrophic changes (increased luminal epithelial cell height) but far less uterine weight gain than estradiol, consistent with partial-agonist rather than full-agonist activity. In mouse uterus, 4-hydroxytamoxifen exposure is uterotrophic (estrogen-agonist-like), contrasting with more antagonist-dominant behavior in rat uterus.